Sarah E Lochrin

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancer

W. Figg, D. Price, Sarah E Lochrin, 2014, Cancer biology & therapy.

Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance

W. Figg, S. Finn, Sarah E Lochrin, 2015, Cancer biology & therapy.

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

S. Steinberg, J. Schlom, W. Figg, 2021, Journal for ImmunoTherapy of Cancer.

Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers

P. Choyke, E. Levy, P. Pinto, 2021, Scientific Reports.

GNRH2 Polymorphism in Men With Prostate Cancer Treated With Androgen Deprivation Therapy

D. Venzon, W. Figg, D. Price, 2023, AntiCancer Research.